Table 2.
LOOCV Test Metrics for “true-pathology” group comparisons.
| ESI-Ion Trap MS Group 1 vs. Group 2 |
Mean (SD) Group 1 |
Mean (SD) Group 2 |
“Effect
Size” |
p Value | N Group 1:Group 2 | Sensitivity | Specificity | Figure# |
|---|---|---|---|---|---|---|---|---|
| moderate-Alzheimer’s disease vs. Control, N = 14 | 62.73% (7.34%) | 28.07% (6.85%) | 4.88 | 6.06 × 10−14 | 16:14 | 1 | 1 | Figure 2A |
| mild-Alzheimer’s disease vs. Control, N = 14 | 63.67% (5.01%) | 37.29% (5.86%) | 4.83 | 4.24 × 10−13 | 15:14 | 1 | 1 | Figure 2C |
| Alzheimer’s disease, N = 31 vs. Control, N = 14 | 49.81% (3.81%) | 28.53% (3.50%) | 5.81 | 3.63 × 10−14 | 31:14 | 1 | 1 | Figure 3A and Figure 4A |
| mild-Alzheimer’s disease vs. moderate-Alzheimer’s disease | 67.33% (4.92%) | 42.66% (5.41%) | 0.77 | 3.25 × 10−14 | 15:16 | 0.93 | 1 | Figure 3C and Figure 4D |
| Training set: Alzheimer’s disease vs. Control | 55.25% (3.15%) | 20.09% (2.36%) | 12.63 | 1.24 × 10−24 | 21:14 | 1 | 1 | Figure 3B |
| mild and moderate-Alzheimer’s disease vs. TBI | 64.12% (4.17%) | 26.78% (6.13%) | 7.12 | 1.53 × 10−14 | 18:13 | 1 | 1 | Figure 4B |
|
ESI-Single-Quad MS
Group 1 vs. Group 2 |
Mean (SD)
Group 1 |
Mean (SD)
Group 2 |
“effect
size” |
p Value | N Group 1:Group 2 | Sensitivity | Specificity | Figure# |
| mild-Alzheimer’s diseasevs. Control, N = 14 | 66.67% (8.80%) | 26.07% (12.74%) | 3.70 | 4.58 × 10−10 | 15:14 | 1 | 1 | Figure 5A |
| moderate-Alzheimer’s diseasevs. Control | 73.14% (7.11%) | 49.35% (11.36%) | 2.51 | 5.12 × 10−7 | 16:14 | 0.93 | 0.86 | Figure 5B |
| Alzheimer’s diseasevs. Control, N = 14 | 44.82% (8.92%) | 27.91% (6.45%) | 2.17 | 1.28 × 10−8 | 31:14 | 0.93 | 0.71 | Figure 5C |
| moderate-Alzheimer’s disease vs. mild-Alzheimer’s disease | 75.56% (8.35%) | 39.42% (11.14%) | 3.67 | 7.75 × 10−11 | 15:16 | 0.93 | 0.94 | Figure 5D |
Leave one out cross validation (LOOCV); mass spectrometer (MS); standard deviation (SD); effect size measured by Cohen’s d; p value measured by Student’s t-test; true negative (TN); false negative (FN).